SMTI
BEARISH
$20.77
Live
Sanara MedTech Inc. · NASDAQ
Target $34.0
(+63.7%)
$16.05
52W Range
$35.95
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 20, 2026
Market cap
$190.4M
P/E
N/A
ROE
-1.8%
Profit margin
-36.4%
Debt/Equity
8.13
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
SMTI exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and an alarming Debt/Equity ratio of 8.13. While the company maintains an impressive gross margin of 92.71%, this is offset by consistent net losses and a track record of massive earnings misses (average surprise of -587.40% over the last 4 quarters). There is a stark disconnect between the 'Strong Buy' analyst consensus and the underlying deterministic health metrics, which suggest high insolvency risk. The stock's long-term price trajectory is sharply negative, despite a recent short-term bounce.
Key Strengths
Exceptional Gross Margin (92.71%) indicating strong product pricing power
Positive Operating Margin (10.50%) suggesting core business viability
Adequate short-term liquidity with a Current Ratio of 1.80
Strong analyst target price ($34.00) relative to current price
Recent short-term price momentum (1W +25.6%)
Key Risks
Extreme leverage with a Debt/Equity ratio of 8.13
Critical financial health indicated by Piotroski F-Score of 2/9
Chronic inability to meet earnings estimates with severe negative surprises
Stagnant revenue growth (4.70% YoY) for a small-cap med-tech firm
Extreme valuation premium on book value (Price/Book of 31.28)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
15
Weak
15
30
20
10
0
AI Verdict
High Risk / Speculative
Key drivers: Extreme Debt/Equity, Poor Piotroski Score, Consistent Earnings Misses, High P/B Ratio
Confidence
90%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
- P/S ratio of 1.85 is relatively modest
Watchpoints
- P/B ratio of 31.28 is unsustainable
- No Graham Number available due to lack of earnings
Future
30/100
Ref Growth rates
Positives
- Positive operating margins
- Bullish analyst targets
Watchpoints
- Very low YoY revenue growth (4.7%)
- Negative profit margins (-36.43%)
Past
20/100
Ref Historical trends
Positives
- Recent 1-month recovery
Watchpoints
- 3-year price decline of 56.6%
- Consistent history of EPS misses
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio above 1.0
Watchpoints
- Piotroski F-Score 2/9 (Weak)
- Debt/Equity 8.13 (Extreme Risk)
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$20.77
Analyst Target
$34.0
Upside/Downside
+63.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for SMTI and closest competitors.
Updated 2026-04-17
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
SMTI
Sanara MedTech Inc.
Primary
|
-25.6% | -56.6% | -29.4% | -26.5% | +11.3% | +25.6% |
|
ARCT
Arcturus Therapeutics Holdings Inc.
Peer
|
-87.2% | -57.7% | -51.9% | -61.4% | -9.7% | -6.0% |
|
RNAC
Cartesian Therapeutics, Inc.
Peer
|
-93.8% | -80.8% | -33.0% | -21.9% | +5.9% | +17.7% |
|
ACB
Aurora Cannabis Inc.
Peer
|
-96.9% | -52.9% | -20.2% | -29.6% | -0.3% | -2.3% |
|
ADAG
Adagene Inc.
Peer
|
-81.2% | +188.8% | +109.6% | +84.4% | +33.2% | +45.4% |
SMT
Sanara MedTech Inc.
Primary
5Y
-25.6%
3Y
-56.6%
1Y
-29.4%
6M
-26.5%
1M
+11.3%
1W
+25.6%
ARC
Arcturus Therapeutics Holdings Inc.
Peer
5Y
-87.2%
3Y
-57.7%
1Y
-51.9%
6M
-61.4%
1M
-9.7%
1W
-6.0%
RNA
Cartesian Therapeutics, Inc.
Peer
5Y
-93.8%
3Y
-80.8%
1Y
-33.0%
6M
-21.9%
1M
+5.9%
1W
+17.7%
ACB
Aurora Cannabis Inc.
Peer
5Y
-96.9%
3Y
-52.9%
1Y
-20.2%
6M
-29.6%
1M
-0.3%
1W
-2.3%
ADA
Adagene Inc.
Peer
5Y
-81.2%
3Y
+188.8%
1Y
+109.6%
6M
+84.4%
1M
+33.2%
1W
+45.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
40.73
PEG Ratio
N/A
P/B Ratio
31.28
P/S Ratio
1.85
EV/Revenue
2.15
EV/EBITDA
18.8
Market Cap
$190.4M
Profitability
Profit margins and return metrics
Profit Margin
-36.43%
Operating Margin
10.5%
Gross Margin
92.71%
ROE
-1.75%
ROA
7.1%
Growth
Revenue and earnings growth rates
Revenue Growth
+4.7%
Earnings Growth
N/A
Q/Q Revenue Growth
+4.72%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
8.13
High debt
Current Ratio
1.8
Good
Quick Ratio
1.53
Excellent
Cash/Share
$1.81
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
93.2%
Op. Margin
10.5%
Net Margin
-5.8%
Total Assets
$0.1B
Liabilities
$0.1B
Equity
$0.0B
Debt/Equity
11.28x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
98%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-12
$N/A
2026-03-24
$-0.19
-272.7% surprise
2025-11-12
$-3.52
-1537.2% surprise
2025-08-13
$-0.23
+47.7% surprise
Healthcare Sector Comparison
Comparing SMTI against 470 companies in the Healthcare sector
(26 bullish, 143 neutral, 301 bearish)
Return on Equity (ROE)
-1.75%
This Stock
vs
-97.91%
Sector Avg
-98.2%
(Below Avg)
Profit Margin
-36.43%
This Stock
vs
-16.16%
Sector Avg
+125.4%
(Superior)
Debt to Equity
8.13
This Stock
vs
3.0
Sector Avg
+170.9%
(Higher)
Revenue Growth
4.7%
This Stock
vs
142.9%
Sector Avg
-96.7%
(Slower)
Current Ratio
1.8
This Stock
vs
4.65
Sector Avg
-61.3%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
SMTI
Sanara MedTech Inc.
|
BEARISH | $190.4M | - | -1.8% | -36.4% | $20.77 | |
|
ARCT
Arcturus Therapeutics Holdings Inc.
|
BEARISH | $189.87M | - | -28.9% | -80.2% | $6.68 | Compare |
|
RNAC
Cartesian Therapeutics, Inc.
|
BEARISH | $186.62M | - | -% | -% | $7.04 | Compare |
|
ACB
Aurora Cannabis Inc.
|
BEARISH | $194.51M | - | -15.5% | -22.5% | $3.43 | Compare |
|
ADAG
Adagene Inc.
|
BULLISH | $194.65M | - | -63.3% | -% | $4.13 | Compare |
SMTI
Sanara MedTech Inc.
BEARISH
Mkt Cap
$190M
P/E
-
ROE
-1.8%
Price
$20.77
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-20 | WALDROP JACOB A. | Chief Operating Officer | Stock Award | 13,956 | - |
| 2026-03-20 | TAYLOR ELIZABETH | Chief Financial Officer | Stock Award | 12,687 | - |
| 2026-03-20 | YON SETH D | Chief Executive Officer | Stock Award | 25,430 | - |
| 2026-03-20 | MACKEY ASHLEY M | Officer | Stock Award | 2,804 | - |
WALDROP JACOB A.
Chief Operating Officer
2026-03-20
13,956 shares
TAYLOR ELIZABETH
Chief Financial Officer
2026-03-20
12,687 shares
YON SETH D
Chief Executive Officer
2026-03-20
25,430 shares
MACKEY ASHLEY M
Officer
2026-03-20
2,804 shares
Insider transactions can signal confidence or concerns about company prospects
SEC Filings
Recent regulatory filings from the SEC EDGAR database
DEF 14A
10-K
8-K
8-K
10-Q
8-K
8-K
Data sourced from SEC EDGAR. AI summaries generated automatically.
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
2 analysts
Lake Street
2026-04-15
Buy
HC Wainwright & Co.
2026-01-26
Buy
Buy
HC Wainwright & Co.
2025-11-14
Buy
Buy
Past News Coverage
Recent headlines mentioning SMTI from our newsroom.
Newest → oldest
No matching news yet.